On June 24, Insilico Medicine rose 6.34% in regular trading, trading at HKD 44.78/share, with turnover of HKD 80.72 million, extending its recent strong momentum.

On the news front, the company announced on June 22 a landmark AI-driven drug R&D collaboration with SK Biopharmaceuticals focused on neuroimmune diseases, with potential total deal value exceeding USD 2.5 billion. Under the agreement, Insilico Medicine is eligible to receive up to USD 18 million in upfront and near-term milestone payments, with the remaining value comprising development, regulatory, and commercialization milestones plus royalties. The positive sentiment from this deal continues to ferment in the market.

At the sector level, the Life Sciences Tools & Services sector rallied broadly, with Wuxi XDC up 10.01%, Wuxi AppTec up 8.1%, GenScript Biotech up 7.73%, and Wuxi Bio up 5.39%, providing further tailwinds through sector resonance. Multiple prior catalysts including the ISM8969 first-in-human dosing milestone and recent index inclusions have also underpinned bullish sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)